Improving Dementia Care in Primary Practice
NCT07526480
Alzheimer Disease, Alzheimer Disease (AD)
View Trial DetailsNCT Number: NCT07422038
The BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) pilot study was launched at Parkwood Hospital in response to national calls for implementation of biomarker diagnostics in Canada. It evaluated the feasibility, impact, and equity of introducing blood biomarker testing, lumbar punctures, and amyloid Positron Emission Tomography (PET) scans into clinical pathways. The study found that the Biomarker-First pathway significantly reduced the time from referral to diagnosis (195 versus 533 days - a difference of 318 days), demonstrating the value in implementing clinical biomarkers to bypass bottlenecks created by the need for specialist assessments. Building on these findings, the next phase of BioMIND is aimed at reducing wait times for biomarker diagnostics for patients with symptoms suggestive of mild cognitive impairment (MCI) and early AD.
The aim is to understand these wait times to biomarker testing using a nurse-led triage support tool. Group A participants will be pre-screened using this tool that includes the eligibility criteria for the study. This will help understand, out of everybody coming to the Aging Brain and Memory Clinic (ABMC) who've indicated interest in research, which people would be eligible to receive AD biomarkers if they were clinically available. Comparison of Group A's time to diagnosis with Group B and C's, who would have had a specialist appointment within 18 months and were referred to research to receive AD biomarkers through this study.
Trial opening soon.
Get Notified50 year–90 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Group A - under 250 days. Group B and C - under 365 days
Will be measured by number of days between referral and disclosure of results
Time frame: throughout study until completion, approximately 2 years
measured by the number of participants in Group A that are biomarker positive for AD compared to the participants who are biomarker negative for AD
Time frame: survey given before results and within 1 month after results are received
determined by pre and post biomarker results surveys and focus group feedback
Time frame: at time of referral
measured by number of participants enrolled in Group C compared to the number of patients referred for testing
Time frame: this will be analyzed at study completion, approximately 2 years. results will be correlated at time of study procedure
measured by the percent agreement between plasma biomarker and CSF results and amyloid PET results
Time frame: through study completion, approximately 2 years.
measured by MoCA, ADL score, ACDS-ADL-MCI
Contact information is provided by the study sponsor or research team.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
Acronym: BioMIND 2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07526480
Alzheimer Disease, Alzheimer Disease (AD)
View Trial DetailsNCT07385937
Alzheimer Disease, Alzheimer Disease (AD)
Murcia, Spain
View Trial DetailsNCT07558785
Alzheimer Disease, Alzheimer Disease (AD)
Pilsen, Czechia
View Trial DetailsNCT03402919
Alzheimer Disease, Alzheimer Disease (AD)
Calgary, Alberta, Canada
View Trial Details